All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2020; the latest 2021-08-13.
From the record
Tango Therapeutics, Inc.'s filings since 2020 show 1 warning event: an auditor change (8-K item 4.01, the latest 2021-08-13) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+52.1% a year over 6 filed years; profitable in 0 of 6.
From the record
Tango Therapeutics, Inc.'s 6 filed years say what it did: revenue went from $8 million in fiscal 2020 to $62 million in fiscal 2025, up 52.1% a year; it rose in 4 of 5 years; the deepest fall was 33% from fiscal 2021 to fiscal 2022; net income was positive in 0 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Tango Therapeutics, Inc.'s shareholder treatment is put at 6.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 35% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -29%: lost 29¢ per shareholder dollar. Leverage 13%: owes 13¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Tango Therapeutics, Inc. lost about 29 cents for every dollar of shareholders' money. Leverage: it owed about 13 cents per dollar of assets, and net share issuance: its share count grew 6.4% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 40% of 315 in its family; net margin -162.9%.
From the record
Tango Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $62 million in fiscal 2025 ranks in the top 42% by size; a net margin of -162.9% ranks in the bottom 50%; revenue growth of 35.9% a year over the last 3 filed years ranks in the top 27% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 18% of 315 in its family for leadership; chief executive since 2026.
From the record
Tango Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Peters, Malte (President & CEO, as filed), filing under that title since 2026-01-12, 10 months (bottom 13% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 3.7 years (bottom 21%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (bottom 19%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 49% of 273 in its family for room to expand.
From the record
Tango Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $112 million against no long-term debt tagged leaves 28.2% of its assets as net cash, top 49% of its family; cash from operations less capital spending is -224.3% of revenue (bottom 42%); research spending of 211.9% of revenue (top 41%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 45% of 306 in its family for growth drivers.
From the record
Tango Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 35.9% a year over the last three filed years against 52.1% over all 6, slowing (bottom 28% of its family); the newest year grew 48.3% (top 26%); research spending grew 7.7% a year (top 42%); capital spending grew -48.5% a year (bottom 23%) (its annual reports). Tango Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 36% of 233 in its family for expectations against reality.
From the record
Tango Therapeutics, Inc.'s newest year against its own record: revenue of $62 million in fiscal 2025 came in 14% above the $55 million its prior three years' pace pointed to (top 31% of its family); net income of $102 million against a prior three-year average of $113 million (bottom 48%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 26%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made